Clinical Trials
13 trialsNCT03919240 2026-06-04
CAR-T Cell Therapy Targeting to CD19 for R/R ALL
The First Affiliated Hospital of Soochow University
Phase 1/2 Active not recruiting
NCT03960840 2026-06-04
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
Novartis
Phase 1/2 Active not recruiting
NCT03114865 2026-06-03
A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Active not recruiting
NCT04195347 2026-06-03
Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase
St. Jude Children's Research Hospital
Phase 1/2 Recruiting
NCT05848687 2026-06-03
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
Stanford University
Phase 1/2 Recruiting
NCT05579132 2026-06-01
MK-1045-002
MSD R&D (China) Co., Ltd.
Phase 1/2 Recruiting
NCT03504644 2026-05-29
Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia
Eastern Cooperative Oncology Group
Phase 1/2 Active not recruiting
NCT04521231 2026-05-28
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
Amgen
Phase 1/2 Active not recruiting
NCT05442515 2026-05-28
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT03573700 2026-05-20
Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital
Phase 1/2 Active not recruiting
NCT07155226 2026-05-19
MOMENTUM
AstraZeneca
Phase 1/2 Recruiting
NCT07387926 2026-05-19
Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
Novartis
Phase 1/2 Not yet recruiting
NCT06308588 2026-05-15
Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Recruiting